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ABSTRACT
Background. Pharmacokinetically guided (PK-guided) versus
body surface area-based 5-fluorouracil (5-FU) dosing results
in higher response rates and better tolerability. A paucity
of data exists on PK-guided 5-FU dosing in the community
setting.
PatientsandMethods. Seventycolorectalcancerpatients, from
one academic and five community cancer centers, received the
mFOLFOX6 regimen (5-FU 2,400 mg/m2 over 46 hours every
2 weeks) with or without bevacizumab at cycle 1. The 5-FU
continuous-infusion dose was adjusted for cycles 2–4 using
a PK-guided algorithm to achieve a literature-based target
area under the concentration-time curve (AUC).The primary
objective was to demonstrate that PK-guided 5-FU dosing
improves the ability to achieve a target AUCwithin four cycles
of therapy. The secondary objective was to demonstrate
reduced incidence of 5-FU-related toxicities.
Results. At cycles 1 and 4, 27.7% and 46.8% of patients
achieved the target AUC (20–25 mg 3 hour/L), respectively
(odds ratio [OR]: 2.20; p 5 .046). Significantly more patients
were within range at cycle 4 compared with a literature rate of
20% (p , .0001). Patients had significantly higher odds of not
being underdosed at cycle 4 versus cycle 1 (OR: 2.29; p5 .037).
The odds of a patient being within range increased by 30%
at each subsequent cycle (OR: 1.30; p 5 .03). Less grade 3/4
mucositis anddiarrheawereobserved comparedwithhistorical
data(1.9%vs16%and5.6%vs12%,respectively);however, rates
of grade 3/4 neutropenia were similar (33% vs 25%–50%).
Conclusion. PK-guided 5-FU dosing resulted in significantly
fewer underdosed patients and less gastrointestinal toxicity
and allows for the application of personalized colorectal
cancer therapy in the community setting. The Oncologist
2014;19:959–965
Implications forPractice:There is consistent support in the literature for a clinically important relationshipbetween5-fluorouracil
(5-FU) exposure and clinical outcomes. Clinical trials reflect the advantage of pharmacokinetically guided 5-FU dosing to enhance
therapeutic outcomes; however, the paucity of interventional studies performed in the community setting partially explains the
lack of assimilation into clinical practice. Our multicenter study demonstrated the practicality of using a simple methodology to
guide 5-FU dosing in the community setting and resulted in significantly fewer underdosed patients and less gastrointestinal
toxicity.These results establish a level of feasibility, andwe believe the data accumulated to date are sufficient to consider further
assessment and use of pharmacokinetically guided 5-FU dosing in clinical practice.
INTRODUCTION
5-Fluorouracil (5-FU) has remained the backbone of colorectal
cancer (CRC) therapy for more than 50 years [1–5]. Compared
with bolus dosing, continuous intravenous infusion of 5-FU
has allowed for higher tolerable doses to be administered
to patients, thereby enhancing clinical effectiveness [6–9].
However, dosing of 5-FU is currently based on body surface
area (BSA), with a resulting 100-fold interindividual pharma-
cokinetic (PK) variability [9].This variation is partially explained
by genetic differences in dihydropyrimidine dehydrogenase
(DPD), the metabolizing enzyme of 5-FU, and differences in
distribution and clearance based on age, weight, sex, disease
state, organ function, and diet [10, 11].When dosed according
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to BSA, 5-FU administration results in up to one-third of
patients developing severe dose-limiting toxicities and 50% of
patients failing to respond to therapy [9, 12]. Previous studies
report that 20%–30% of patients treated with conventional
dosing have 5-FU exposure levels within a previously estab-
lished therapeutic range (area under the concentration-time
curve [AUC] 20–25 mg 3 hours/L [h/L]), whereas approx-
imately 40%–60% and 10%–20% are under and over this
therapeutic AUC threshold, respectively [13].
The suggested AUC target of 20–25 mg 3 h/L and the
clinical validity of PK-guided 5-FU dosing have been demon-
strated in several studies [9, 14–17]. Gamelin et al. initially
observed a close relationship between acute toxicity and
AUC0–8 hours .24 mg 3 h/L in 40 CRC patients [18].
Subsequently, a phase II PK-guided trial in 158 CRC patients
targeting an AUC0–8 hours 16–24 mg 3 h/L demonstrated
median overall survival (OS) of 19 months and an objective
response rate (ORR) of 43.4% [9], approximately double the
expected response rate of 5-FU and leucovorin administered
by standard dosing. A randomized trial of 208 stage IV CRC
patients receiving either conventionally dosed 5-FU or
PK-guided 5-FU targeting an AUC 20–24 mg 3 h/mL
demonstrated ORRs of 18.3% and 33.7% (p 5 .004),
respectively, and median OS of 16 and 22 months (p 5 .08),
respectively [16]. A similar trial comparing conventionally
dosed 5-FU and PK-guided 5-FU in patients receiving the
FOLFOX regimen (5-FU, oxaliplatin, leucovorin) identified
ORRs of 46% and 69.5%, respectively, and median OS of 22
and 28 months, respectively, along with decreased incidence
of grade 3/4 diarrhea and mucositis in the PK-guided dosing
group [15].
To date, PK-guided 5-FU dosing has not been widely
integrated into clinical practice, in part because of the paucity
of data that demonstrates the ability to personalize 5-FU
dosing in the community setting [13]. Given the evidence for
PK-guided therapy, we conducted a multicenter study to
investigate the application of PK-guided 5-FU dosing in
a predominantly community setting, using a commercially
available single-sample immunoassay to measure drug
exposure. The primary objective was to demonstrate the
ability to achieve a target AUC (20–25 mg3 h /L) within four
cycles of therapy in CRC patients receiving modified FOLFOX6
with or without bevacizumab. The secondary objective was
to demonstrate that PK-guided 5-FU dosing decreases the
incidence of 5-FU-related toxicities, including neutropenia,




Patients from one academic and five community cancer
centers scheduled to receive planned treatment with mFOL-
FOX6 with or without bevacizumab for histologically con-
firmed CRC (adjuvant or metastatic) were eligible to
participate in the study. All patients were required to have
an Eastern Cooperative Oncology Group performance status
#2; have life expectancy of .6 months; provide written
informedconsent; andhaveadequatebonemarrowandorgan
function, defined as absolute neutrophil count$1,500/mm3,
platelets$100,000/mm3, serum creatinine#1.5mg/dL, total
bilirubin#1.5 timesupper limitofnormal (ULN),andaspartate
andalanineaminotransferase#2.53ULN(or#53ULNin the
presence of liver metastases).
Patients were not eligible if they were pregnant, had
serious concomitant systemic disorders, or were unable to
refrain from eating chocolate from any source beginning 12
hours prior to day 1 of each cycle and throughout the 46-hour
5-FU continuous infusion (CIV; theobromine, a compound
found in chocolate, interferes with the assay and results in
falsely elevated AUCs). Patients taking warfarin, enoxaparin,
aminophylline, or theophylline were excluded from the study.
Patients were considered eligible for analysis if they
completed four cycles of plannedmFOLFOX6 with PK samples
obtained at each cycle. In addition, patients removed from
PK-guided therapy secondary to toxicity and those with only
one missing PK sample (not due to a sampling error) were
included in theanalysis. Patientswereexcluded fromanalysis if
5-FUwasdosedbyanyothermeansnot includingPKor toxicity
or if therewere concerns about 5-FU test-result validity due to
sampling and/or processing errors.
The trial protocolwas approved by the institutional review
boards of all trial sites, and informed consent was obtained
from each participant prior to enrollment.
Treatment and Dose Adjustment
All patients receivedmFOLFOX6atcycle1:oxaliplatin 85mg/m2
over 2 hours, leucovorin 200–400 mg/m2 over 2 hours, 5-FU
400 mg/m2 bolus, 5-FU 2,400 mg/m2 CIV over 46 hours (via
a battery-operated pump) with or without bevacizumab, as
determinedby theprimary treatingphysician.The5-FUpumps
were prefilled at central infusion pharmacies, primed with
saline, and estimated to deliver drug within 30 minutes.
Subsequent cycles were repeated every 2 weeks. Oxaliplatin,
leucovorin, and 5-FU bolus dosage remained the same
throughout treatment (unless adjusted for toxicity), whereas
the5-FUCIVdosewasadjusted forcycles2–4usingaPK-guided
dose-adjustment algorithm targeting an AUC range of 20–25
mg3 h/L (Table 1).
During cycles 1–4, a peripheral blood samplewas obtained
2–44 hours after the start of the continuous infusion into an
EDTA tube. Given that the half-life of 5-FU is approximately 10
minutes (62minutes) [6], steady state should theoretically be
achieved within 1 hour. A stabilizing agent (derivative of uracil
with properties that irreversibly inhibit DPD)was added to the
sample immediately. The EDTA tube was inverted at least 3
timesandcentrifugedat2,000g for10–15minutes.Theplasma
waspipetted fromthe sample intoa3-mLcryovial tube labeled
with a bar code. A test request formwas completed, including
the infusion start time, draw time, infusion duration, patient
identification, diagnosis, and dose. The sample was mailed to
Myriad Genetics, Inc. (Salt Lake City, UT, https://www.myriad.
com) for AUC analysis using a nanoparticle-based immuno-
assay. AUC is determined by multiplying the steady-state
concentration by infusion duration.
Beginning with cycle 2, the 5-FU CIV dose was adjusted
before each cycle according to an algorithm based on the
results of the AUC from the preceding cycle, with a target AUC
of 20–25 mg3 h/L (Table 1). The dose adjustment algorithm
was based on a linear relationship observed between plasma
©AlphaMed Press 2014
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levels and5-FUdoseandhasbeenpublishedpreviously [9, 16].
In the event the AUC dropped out of the target AUC range in
a subsequent cycle, the5-FUCIVdosewas readjustedbasedon
the algorithm.
Follow-Up and Patient Monitoring
Patients underwent biweekly physical examinations and
toxicity assessment before administration of each of the first
five cycles. In addition, documentation of concomitant med-
ications and foods were recorded at each cycle. The last
toxicity assessment was made prior to receiving cycle 5.
Assessment of Toxicity
Patients underwent biweekly physical examinations and
toxicity assessment using the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events version 3.0
before administration of each of the first five cycles. Dose
reductions for clinical toxicity are described in Table 1. For
patients experiencing no toxicity or grade #1, the dose
adjustmentwasmade according to the algorithm. In the event
that a patient experienced a 5-FU-related toxicity of grade$2
but had an AUC value that was below the target, the toxicity
and subsequent dose reduction took precedence over the
PK-guided dose escalation. In the event of a grade 2 non-
hematologic toxicity associated with 5-FU (diarrhea, hand-
foot syndrome, or mucositis), the dose was reduced at the
discretion of the primary treating oncologist. In the event of
grade 3 nonhematologic toxicity or grade 4 hematologic
toxicity, 5-FU treatment was withheld until recovery of the
toxicity tograde#2andrestartedwitha20%dosereductionof
bolus and CIV 5-FU. Patients were removed from the study in
cases of grade 4 nonhematologic toxicity. Toxicity data were
collected through a secure Web-based clinical research
platform, OnCore (Forte Research Systems, Madison, WI,
https://forteresearch.com/enterprise-research-oncore/).
Statistical Analyses
For the primary objective of demonstrating an increased
percentageofpatients in rangebycycle4usingPK-guideddose
adjustments versus non-PK-guided adjustments, a null hy-
pothesis of 20% was used based on historical data [15, 16].
Using a 1-sided significance level of .05 and a 1-sample exact
binomial test, a sample size of 50 had 72% power to detect
a difference of 15% (alternative hypothesis of 35%) and 90%
power to detect a difference of 20%. Comparisons between
toxicity rates of patients receiving and not receiving bevaci-
zumab and those with and without dose escalations were
made using Fisher’s exact tests. Generalized linear models
were used to perform logistic regression while accounting
for multiple cycles per patient. In addition to estimating
odds ratios (ORs) for being in range at cycle 4 versus cycle 1,
not beingunderdosed, andbeing in rangeat each subsequent
cycle, this method was used to evaluate the associa-
tion between AUC range and grade 3/4 toxicities over all
cycles.
RESULTS
Seventy-five patients gave informed consent for the study
between May 2010 and October 2012, with five patients
subsequently not receiving treatment. Of the remaining 70
patients receivingmFOLFOX6withorwithoutbevacizumab,16
patients were removed from the study secondary to protocol
violations (n 5 14) and patient preference (n 5 2). The
remaining 54 patients were deemed evaluable for “any-cycle”
analyses, including PK and/or toxicity (Fig. 1). Baseline
characteristics are summarized in Table 2. Of the 54 patients
evaluable for any-cycle analyses, 25 (46.2%) had metastatic
disease and 18 (33.3%) received bevacizumab in addition to
chemotherapy. Four patients discontinued the study second-
ary to toxicity, and6patients had1missingblood sample forPK
analysis (3 at cycle 2 or 3 and 3 at cycle 4), resulting in 44
patients with an evaluable PK sample at all 4 cycles and 47
patientswith an evaluable PK sample at cycles 1 and 4. Sixteen
of the 54 evaluable patients were treated and enrolled at the
University of North Carolina (UNC) Cancer Hospital, whereas
the remaining 38 were treated and enrolled at community-
based hospitals within the UNC Cancer Network.
5-FU Exposure as Measured by AUC
The odds of a patient achieving the target AUC increased from
cycle 1 (27.7%; 13 of 47) to cycle 4 (46.8%; 22 of 47) (OR: 2.20;
95% confidence interval [CI]: 1.01–4.76; p 5 .046). With an
exact binomial CI of (32.1%–61.9%) for the percent of patients
in range by cycle 4 (46.8%), PK-guided 5-FU dosing resulted in
significantly more patients within the prespecified AUC range
compared with a historical rate of 20% (p, .0001), satisfying
the primary objective. In addition, patients had significantly
higher odds of not being underdosed (i.e., not having an AUC
,20 mg 3 h/L) at cycle 4 versus cycle 1 (OR: 2.29; 95% CI:
1.05–4.96; p5 .037).The odds of a patient being within range
increased by 30% at each subsequent cycle (OR: 1.30; 95% CI:
1.03–1.66; p5 .03) using the defined algorithm.
Figure 2A demonstrates the percentage of patients below,
within, and above the prespecified AUC threshold for all
evaluable patients in the any-cycle analysis (n 5 54) at each
independentcycle.At cycle1, 29.6%ofpatients (16of 54)were
within range, compared with 46.8% (22 of 47) at cycle 4.
Figure2Bdemonstrates the cumulative percentageof patients
achieving the target AUC from cycle 1 to cycle 4. The median
Table 1. 5-Fluorouracil dose adjustment algorithm






AUC,4 170 Grade 2: oncologist
discretion4# AUC, 8 150
8# AUC, 10 140 Grade 3 nonhematologic:
delay until recovery
to grade,2 and resume
with 20% dose reduction
10# AUC, 12 130
12# AUC, 15 120
15# AUC, 18 110 Grade 4 hematologic:
delay until recovery
to grade,2 and resume
with 20% dose reduction
18# AUC, 20 15
20# AUC# 25 No change
25, AUC, 28 25 Grade 4 nonhematologic:
remove from study, treat
at physician discretion
28# AUC# 31 210
31, AUC 215
Abbreviation: AUC, area under the concentration-time curve.
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AUCs at cycle 1 for men and womenwere 19 and 21mg3 h/L
(not statistically significant), respectively, consistent with
previous literature reporting lower DPD enzyme activity and
higher 5-FU exposure in female patients compared with male
patients [19]. No significant differences were noted in median
AUC between bevacizumab- and non-bevacizumab-treated
patients (p5 .76).
There was evidence of intrapatient variability in assay
results, with 80% of all patients (43 of 54) achieving the target
AUC during at least 1 of the 4 cycles and no patients within
range at every cycle. The coefficient of variation in AUC de-
creased from 30.6% to 24.9% for cycles 1 and 4, respectively.
The trend toward decreased PK variability and fewer patients
underdosed at cycle 4 is reflected in an increase of themedian
AUC from 19 to 21 mg3 h/L.
Moreover, 76% of patients (41 of 54) required a protocol-
guided dose increase at any point during the 4 cycles of
PK-guided therapy. Of these 41 patients, 27 (66%) required
their first dose increase prior to the administration of cycle 2.
The median 5-FU dose necessary for patients successfully
achieving the targeted AUC at cycle 4 was 2,5806 377mg/m2
(range: 1,925–3,484mg/m2; supplemental online Fig. 1 shows
a bar graph of patients’ cycle 4 dose).
Toxicity
As indicated in Table 3, the incidence of grade3/4 neutropenia
was similar in patients treated with PK-guided mFOLFOX6
compared with historical non-PK-guided mFOLFOX6 (33% vs.
25%–50%); however, a decrease in the incidence of grade 3/4
diarrhea and mucositis was noted (5.6% vs. 12% and 1.9% vs.
15%, respectively) (Table 3).
The incidence of grade 3/4 neutropenia was similar for
cycles during which the target AUC was achieved (8.9%)
comparedwithcyclesduringwhich theAUCwas,20mg3h/L
(8.1%). However, a higher incidence of grade 3/4 neutropenia
Figure 1. CONSORT diagram. aSample drawn after pump finished infusing, sample not analyzed secondary to labeling issues; patient
given hydration via peripheral line and sample drawn without wasting, thus diluted; omission of stabilizing agent and/or blood sample
hemolyzed. In addition, three of these patients had protocol violations such as per-protocol dose adjustment notmade. bAll four patients
completed two cycles of PK-guided 5-FU prior to being removed.
Abbreviations: 5-FU, 5-fluorouracil; mFOLFOX6, modified FOLFOX regimen (5-FU, leucovorin, oxaliplatin); PK, pharmacokinetic.
Table 2. Baseline patient characteristics
Characteristic Result









Stage II 2 (3.8)
Stage III 27 (50)
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was observed in cycles during which AUC was.25 mg3 h/L
comparedwith,20mg3h/L (21.6%vs. 8.1%,p5 .05) (Fig. 3).
Significantly higher rates of any grade 3/4 toxicity (e.g.,
neutropenia, diarrhea, mucositis, fatigue, nausea or vomiting)
werenoted inpatientswithAUC.25mg3h/L comparedwith
AUC,20 mg3 h/L (32.4% vs. 12.8%, respectively; p5 .007)
(Fig. 3). Importantly, of the patients having a PK-guided dose
escalation at any cycle with no toxicities prior to the increase,
40.5% (15 of 37) had any grade 3/4 toxicity at any cycle after
doseescalation comparedwith69.2% (9of 13) of patientswho
didnothaveaPK-guideddoseescalation (p5 .1).This suggests
that PK-guided dose escalations did not result in significantly
higher rates of toxicity compared with patients who did not
require a dose escalation; however, a larger sample size would
be needed to confirm this observation.
DISCUSSION
There is consistent literature of support for a clinically im-
portant relationship between 5-FU exposure and both tox-
icity and efficacy [14, 17, 18, 20, 21]. These studies reflect
the advantage in utilizing PK-guided 5-FU dosing to enhance
therapeutic outcomes.Thepaucityofprospective intervention
studies and few data from the community setting partially
explain the lack of assimilation into clinical practice. Given the
current evidence for PK-guided therapy and considering that
85% of U.S. cancer patients are diagnosed and treated in the
community setting [22],ourmulticenterstudy investigatedthe
application of PK-guided 5-FU dosing across one academic and
five community cancer centers in North Carolina.
PK-guided 5-FU dosing resulted in significantly more
patients achieving a prespecified target AUC and significantly
greateroddsofapatientnotbeingunderdosedandreducedPK
variability. The concept of underdosing of chemotherapy is
a rarely discussed aspect of current dosage-calculation
strategies [12]. Consistent with previous literature, more than
half of all patients (52%) in our studywereunderdosed at cycle
1, as indicatedbyanAUC,20mg3h/L.Themedian5-FUdose
necessary for patients successfully achieving the target AUC at
cycle 4 was 108% (range: 80%–145%) of the recommended
2,400-mg/m2dose (similar to the110% foundbyCapitain et al.
in PK-guided FOLFOX [15] but less than the 119% found by
Gamelin et al. [16] in PK-guided 5-FU alone). However, a nearly
twofold range in dosing was required to achieve the targeted
AUC range. Among the 15 patients who were still under the
AUC threshold at cycle 4, 9 had toxicity-based dose reductions
at cycle 4 that took precedence over a PK-guided dose
adjustment and likely resulted in an AUC ,20 mg 3 h/L.
Considering that 28 of 54 patients were underdosed at cycle
1 and only 6 of those patients who received a PK-guided dose
adjustment for cycle 4 remained under theAUC threshold, this
suggests that close to 80% of eligible patients can avoid
underdosing by using PK-guided 5-FU dosing.
Large intrapatient variations in 5-FU exposure were
evident as 80% of patients achieved the target AUC at any
cycle while only 47% remained within range at cycle 4.
Variations may be due to administration time (circadian
rhythm), PK sampling time, diet, concomitant medications,
andotherenvironmental factors.Targetinga limited therapeu-
ticAUCrangeof20–25mg3h/Lprovidesachallenge inapplying
PK-guided 5-FU dosing in clinical practice. Consequently, recent
data suggest that a wider range of 20–30 mg3 h/L results in
greater success of achieving the target AUC and increased
response without compromising safety [23]. However, this
range has not been evaluated in a randomized clinical trial.
The 5-FU-associated toxicities observed in our study were
consistent with the literature and included neutropenia,
diarrhea, mucositis, stomatitis, nausea, vomiting, and fatigue.
Despite 76% of patients receiving protocol-specified dose
escalations, our studydemonstrated increased tolerability and
decreased rates of grade 3/4 diarrhea and mucositis and
stomatitis compared with historical controls, consistent with
previously published PK-guided 5-FU literature [9, 15, 16, 24].
Although this finding goes against the basic principles of
pharmacology, the fact that4separatePK-guided5-FUtrials [9,
15, 16], totaling 420 colorectal cancer patients (including this
study), resulted in fewer underdosed patients and lower rates
of toxicity is of tremendous importance when considering its
clinical applicability. Interestingly, there was no difference in
the percentage of patients with an AUC .25 mg 3 h/L
throughout all 4 cycles; however, higher rates of any grade 3/4
toxicity were observed in cycles with an AUC .25 mg 3 h/L
(largely driven by grade 3/4 neutropenia).
Figure 2. Percentage of patients below, within and above the
prespecified area under the concentration-time curve (AUC)
threshold at each cycle. (A): Significantly more patients were
within range and significantly less were underdosed at cycle 4
comparedwith cycle 1 (p, .05).The percentages are reflective of
the total number of independent patient samples at each cycle
(i.e., patients with an AUC .25 mg 3 h/L at cycle 1 are not
necessarily the same patients with an AUC .25 mg 3 h/L at
cycle 4). aNumber of patients with an evaluable blood sample for
AUC analysis at each cycle. (B): Cumulative percentage of patients
achieving the target AUC at each cycle. aNumber of patients with
an evaluable blood sample for AUC analysis at each cycle.
Abbreviation: C, cycle.
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The number of patients deemed “nonevaluable” (n5 16)
throughout the course of the study was unexpectedly high,
demonstrating the challenges of conducting a multicenter
study in the outpatient setting when specialized testing is
required. This also potentially speaks to the generalizability of
this approach in the community setting and suggests that
experience and training would be necessary to correctly
implement this dosing approach. Fourteen patients had
protocol violations that resulted in ineligibility, including
samples being drawn after completion of infusion, sample
dilution, omission of sample stabilizing agent, inadequate
labelingof tubes, andper-protocoldoseadjustmentnotmade.
Although factors such as patient compliance with returning
to the clinic for PK sampling were beyond the control of the
investigators, human errors involving sample handling
were more frequent reasons for patient withdrawal after
enrollment. This underscores the need for more attention to
appropriate logistical training and coordination with
patients about the reason for specific timing of office visits
when personalized medicine strategies are being imple-
mented in clinical practice. This is particularly critical for
community-based practices with little experience in sample
handling and clinical research. As a major barrier to wide-
spread adoption, logistical issues must be addressed before
implementation of PK-guided 5-FU dosing can be successful
and effective.
The principal limitation of our study was the single-arm
design, which did not allow for direct comparison of differing
dosing strategies regarding toxicity. Inclusion of patients
receiving both metastatic and adjuvant therapy also prevents
the ability to draw conclusions about efficacy. However, to our
knowledge, our study is theonlyprospectivemulticenter study
utilizing a simplified, clinically applicable methodology for
assessing 5-FU exposure in the outpatient setting, potentially
allowing greater generalizability of results to the oncology
community.
Proof-of-principle personalized chemotherapy dosing is
noted inprospective studiesofdrugs includingcarboplatin [25,
26], high-dosemethotrexate (HDMTX) [27], busulfan [28], and
5-FU [9, 15, 16] that confirm exposure-response relationships
and decreased PK variability. In all of these cases, PK-guided
dosing resulted in fewer patients underdosed, fewer toxicities,
and improved outcomes [29]; however, in contrast to
carboplatin, HDMTX, and busulfan, PK-guided 5-FU dosing
has not been applied as a standard in clinical practice. Patients
receiving PK-guided dosing may experience better outcomes
than thoseobserved forpatients receivingnewerbutverycostly
targeted therapies or those from PK-guided monotherapy
(i.e., 5-FU) versus conventionally dosed combination therapy
(i.e., FOLFOX). In addition, PK-guided therapy may be more
applicable to certain populations such as the elderly, for whom
toxicity from “standard” therapy is often a practical concern.
CONCLUSION
The use of BSA-guided 5-FU dosing has resulted in significant
underdosing of the majority of colorectal cancer patients. It is
imperative to increase the general awareness of the beneficial
effectsandpracticalityofPK-guided5-FUdosing.We identified
multiple barriers to the successful implementation of PK-
guided 5-FU dosing in clinical practice, including sampling
times and coordination. Our study demonstrated that use of
a simple methodology, along with appropriate logistical
training, allows for the application of personalized 5-FUdosing
in colorectal cancer patients treated in the community setting.
ACKNOWLEDGMENTS
This study was funded by an investigator-initiated research
grant to Howard L. McLeod from Myriad Genetics, Inc. Jai N.
Patel and ChristineM.Walko received salary support from this
Figure 3. Rates of toxicity at each area under the concentration-
timecurve (AUC) rangeduring thecycleatwhich toxicityoccurred.
aA significantly higher incidence of grade 3/4 neutropenia was
observed in cyclesduringwhichAUCwas.25mg3h/Lcompared
with cycles during which AUC was ,20 mg 3 hour/L (21.6% vs.
8.1%; p5 .05). bSignificantly higher rates of any grade 3/4 toxicity
(e.g., neutropenia, diarrhea,mucositis, fatigue,nauseaorvomiting)
were noted in patients with an AUC.25mg3 h/L comparedwith
AUC,20 mg3 h/L (32.4% vs. 12.8%, respectively; p5 .007).
Table 3. Toxicity assessment
Toxicity
Study population, n (%)
Historical non-PK-guided
5-FU, grade 3/4 (%)
Historical PK-guided











Diarrhea 24 (44.4) 3 (5.6) 12 12 1.7
Fatigue 29 (53.7) 3 (5.6) 12 NR NR
Mucositis/stomatitis 14 (25.9) 1 (1.9) 16 15 0.8
Nausea/vomiting 27 (50) 2 (3.7) 9 NR NR
Neutropenia 25 (46.3) 18 (33.3) 50 25 18
Abbreviations: 5-FU, 5-fluorouracil; NR, not reported; PK, pharmacokinetic.
©AlphaMed Press 2014
TheOncologist®
964 Pharmacokinetic-Guided 5-FU Dosing
grant. The contents of this manuscript have been published
and presented in part at the 2013 American Society of Clini-
cal Oncology annual meeting. The study is registered on
ClinicalTrials.gov (identifier: NCT01164215).
AUTHOR CONTRIBUTIONS
Conception/Design: Jai N. Patel, Bert H. O’Neil, Joseph G. Ibrahim, Howard L.
McLeod, Christine M.Walko
Provision of study material or patients: Jai N. Patel, Bert H. O’Neil, Gary B.
Sherrill, Oludamilola A. Olajide, Prashanti M. Atluri, John J. Inzerillo,
Christopher H. Chay, Howard L. McLeod, Christine M.Walko
Collection and/or assembly of data: Jai N. Patel, Bert H. O’Neil, AllisonM.Deal,
Howard L. McLeod, Christine M.Walko
Data analysis and interpretation: Jai N. Patel, Bert H. O’Neil, Allison M. Deal,
Joseph G. Ibrahim, Howard L. McLeod, Christine M.Walko
Manuscript writing: Jai N. Patel, Bert H. O’Neil, Allison M. Deal, Joseph G.
Ibrahim, Howard L. McLeod, Christine M.Walko
Final approval of manuscript: Jai N. Patel, Bert H. O’Neil, Allison M. Deal,
Joseph G. Ibrahim, Gary B. Sherrill, Oludamilola A. Olajide, Prashanti M.
Atluri, John J. Inzerillo, Christopher H. Chay, Howard L. McLeod, Christine
M.Walko
DISCLOSURES
Jai N. Patel:Myriad Genetics, Inc. (RF); John J. Inzerillo: Teva (H,
speaker program, OI); Lilly (H, speaker program); Howard L. McLeod:
Gentris Corporation (C/A). The other authors indicated no financial
relationships.
(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert
testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/
inventor/patent holder; (SAB) Scientific advisory board
REFERENCES
1. Poon MA, O’Connell MJ, Wieand HS et al.
Biochemical modulation of fluorouracil with leuco-
vorin: Confirmatory evidence of improved thera-
peutic efficacy in advanced colorectal cancer. J Clin
Oncol 1991;9:1967–1972.
2. PinedoHM,PetersGF.Fluorouracil: Biochemistry
and pharmacology. J Clin Oncol 1988;6:1653–1664.
3. de Gramont A, Bosset JF, Milan C et al.
Randomized trial comparing monthly low-dose
leucovorin and fluorouracil bolus with bimonthly
high-dose leucovorin and fluorouracil bolus plus
continuous infusion for advanced colorectal cancer:
A French intergroup study. J Clin Oncol 1997;15:
808–815.
4. de Gramont A, Figer A, Seymour M et al.
Leucovorin and fluorouracil with or without oxali-
platin as first-line treatment in advanced colorectal
cancer. J Clin Oncol 2000;18:2938–2947.
5. Douillard JY, Cunningham D, Roth AD et al.
Irinotecan combined with fluorouracil compared
with fluorouracil alone as first-line treatment for
metastatic colorectal cancer: A multicentre rando-
mised trial. Lancet 2000;355:1041–1047.
6. Lokich JJ, Ahlgren JD,Gullo JJ et al. Aprospective
randomized comparison of continuous infusion
fluorouracil with a conventional bolus schedule in
metastatic colorectal carcinoma: A Mid-Atlantic
Oncology Program Study. J Clin Oncol 1989;7:425–
432.
7. Diaz-Rubio E, Aranda E, Martin M et al.Weekly
high-dose infusion of 5-fluorouracil in advanced
colorectal cancer. Eur J Cancer 1990;26:727–729.
8. Ardalan B, Chua L,Tian EMet al. A phase II study
of weekly 24-hour infusion with high-dose fluoro-
uracil with leucovorin in colorectal carcinoma. J Clin
Oncol 1991;9:625–630.
9. GamelinE,Boisdron-CelleM,DelvaRetal. Long-
term weekly treatment of colorectal metastatic
cancer with fluorouracil and leucovorin: Results of
a multicentric prospective trial of fluorouracil
dosage optimization by pharmacokinetic monitor-
ing in152patients. J ClinOncol 1998;16:1470–1478.
10. Diasio RB, Johnson MR. Dihydropyrimidine
dehydrogenase: Its role in 5-fluorouracil clinical
toxicity and tumor resistance. Clin Cancer Res 1999;
5:2672–2673.
11.Milano G, EtienneMC, Cassuto-Viguier E et al.
Influence of sex and age on fluorouracil clearance. J
Clin Oncol 1992;10:1171–1175.
12.Walko CM, McLeod HL.Will we ever be ready
for blood level-guided therapy? J Clin Oncol 2008;
26:2078–2079.
13. SaifMW, Choma A, Salamone SJ et al. Pharma-
cokineticallyguideddoseadjustmentof5-fluorouracil:
A rational approach to improving therapeutic out-
comes. J Natl Cancer Inst 2009;101:1543–1552.
14.Milano G, Roman P, Khater R et al. Dose versus
pharmacokinetics for predicting tolerance to 5-day
continuous infusion of 5-FU. Int J Cancer 1988;41:
537–541.
15. Capitain O, Asevoaia A, Boisdron-CelleM et al.
Individual fluorouracil dose adjustment in FOLFOX
based on pharmacokinetic follow-up compared
with conventional body-area-surface dosing: A
phase II, proof-of-concept study. Clin Colorectal
Cancer 2012;11:263–267.
16. Gamelin E, Delva R, Jacob J et al. Individual
fluorouracil dose adjustment based on pharmaco-
kinetic follow-up compared with conventional
dosage: Results of a multicenter randomized trial
of patients with metastatic colorectal cancer. J Clin
Oncol 2008;26:2099–2105.
17.Milano G, EtienneMC, Renée N et al. Relation-
ship between fluorouracil systemic exposure and
tumor response and patient survival. J Clin Oncol
1994;12:1291–1295.
18. Gamelin EC,Danquechin-Dorval EM,Dumesnil
YF et al. Relationship between 5-fluorouracil (5-FU)
dose intensity and therapeutic response in patients
withadvancedcolorectal cancer receiving infusional
therapy containing 5-FU. Cancer 1996;77:441–451.
19.Mattison LK, Fourie J, Desmond RA et al.
Increased prevalence of dihydropyrimidine dehy-
drogenase deficiency in African-Americans com-
pared with Caucasians. Clin Cancer Res 2006;12:
5491–5495.
20. Schneider M, Etienne MC, Milano G et al.
Phase II trial of cisplatin, fluorouracil, and pure
folinic acid for locally advanced head and neck
cancer: A pharmacokinetic and clinical survey. J Clin
Oncol 1995;13:1656–1662.
21. van Kuilenburg AB, Maring JG. Evaluation of
5-fluorouracil pharmacokinetic models and thera-
peutic drug monitoring in cancer patients. Pharma-
cogenomics 2013;14:799–811.
22. Zaren HA, Nair S, Go RS et al. Early-phase
clinical trials in the community: Results from the
National Cancer Institute Community Cancer Cen-
ters Program Early-Phase Working Group baseline
assessment. J Oncol Pract 2013;9:e55–e61.
23. Kaldate RR, Haregewoin A, Grier CE et al.
Modeling the 5-fluorouracil area under the curve
versus dose relationship to develop a pharmacoki-
netic dosingalgorithm for colorectal cancer patients
receiving FOLFOX6. The Oncologist 2012;17:296–
302.
24. Duffour J, Roca L, Bressolle F et al. Clinical
impact of intesified 5-fluorouracil-based chemo-
therapy using a prospective pharmacokinetically-
guided dosing approach: Comparative study in
elderly and non-elderly patients with metastatic
colorectal cancer. J Chemother 2010;22:179–185.
25. Calvert AH, Newell DR, Gumbrell LA et al.
Carboplatin dosage: Prospective evaluation of
a simple formula based on renal function. J Clin
Oncol 1989;7:1748–1756.
26. Jodrell DI, Egorin MJ, Canetta RM et al.
Relationships between carboplatin exposure and
tumor responseand toxicity inpatientswithovarian
cancer. J Clin Oncol 1992;10:520–528.
27. Evans WE, Relling MV, Rodman JH et al.
Conventional comparedwith individualized chemo-
therapy for childhood acute lymphoblastic leuke-
mia. N Engl J Med 1998;338:499–505.
28. Kangarloo SB, Naveed F, Ng ES et al. De-
velopment and validation of a test dose strategy for
once-daily i.v. busulfan: Importanceof fixed infusion
rate dosing. Biol BloodMarrow Transplant 2012;18:
295–301.
29. Beumer JH. Without therapeutic drug moni-
toring, there is no personalized cancer care. Clin
Pharmacol Ther 2013;93:228–230.
See http://www.TheOncologist.com for supplemental material available online.
www.TheOncologist.com ©AlphaMed Press 2014
Patel, O’Neil, Deal et al. 965
